Background: Recent advances in immunotherapy have spotlighted macrophages as central mediators of disease treatment. Their polarization into pro‑inflammatory (M1) or anti‑inflammatory (M2) states critically influences outcomes in cancer, autoimmunity, and chronic inflammation. Oligonucleotides have emerged as highly specific, scalable, and cost‑effective agents for reprogramming macrophage phenotypes.Objective: To review oligonucleotide strategies—including ASOs, siRNAs, miRNA mimics/inhibitors, and aptamers—for directing macrophage polarization and their therapeutic implications.Review Scope: We examine key signaling pathways governing M1/M2 phenotypes, describe four classes of oligonucleotides and their mechanisms, and highlight representative preclinical and clinical applications.Key Insights: Agents such as AZD9150, MRX34, and AS1411 demonstrate macrophage reprogramming in cancer, inflammation, and infection models. Advances in ligand‑conjugated nanoparticles and chemical modifications improve delivery and stability, yet immunogenicity, off‑target effects, and formulation challenges remain significant barriers.Future Perspectives: Optimizing delivery platforms, enhancing molecular stability, and rigorous safety profiling are critical. Integration with emerging modalities—such as engineered CAR‑macrophages—will enable precise, disease‑specific interventions, and advance oligonucleotide‑guided macrophage modulation toward clinical translation.
9 September 2026 in Biotechnology and Bioengineering
Over the past few decades, the landscape for multiple myeloma (MM) therapy has significantly advanced, largely due to the approval and introduction of new-generation proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs). Despite these advancements, MM remains incurable. In March 2021, the U.S. FDA approved the chimeric antigen receptor T-cell (CAR-T) therapy idecabtagene vicleucel (ide-cel) for relapsed/refractory multiple myeloma (R/R MM), heralding the advent of cellular therapies for R/R MM. However, due to factors such as the downregulation or loss of tumor antigen expression, T-cell exhaustion, and the influence of the tumor immune microenvironment, most R/R MM patients inevitably experience relapse following CAR-T cell therapy. Consequently, salvage therapy in the post-CAR-T setting has emerged as a critical area of research. This review discusses the potential factors leading to CAR-T therapy failure in R/R MM patients and discusses subsequent salvage therapeutic strategies, offering recommendations for addressing treatment failure in this context.
Vero cells are an validated continuous substrate for human viral vaccine manufacturing. Decades of performance improvements have relied on extrinsic process optimization; however, intrinsic genomic instability, including segmental aneuploidy and dynamic chromatin rearrangements, are currently limiting the durability of engineered phenotypes under sustained viral burden and bioreactor stress. In this Perspective, we examine how a conceptual transition from empirical permissiveness toward genome-informed architectural redesign could substantially expand the manufacturing capabilities of the Vero platform. We organize the emerging landscape of Vero cell engineering across three interdependent functional layers: the membrane interface, where receptor redesign and suspension adaptation extend viral entry range and culture scalability; the cytoplasmic foundry, where metabolic flux management, ER stress buffering, and temporally controlled apoptosis modulation address production bottlenecks; and the nuclear blueprint, where epigenetic insulation and genomic precision engineering determine the long-term durability of all upstream gains. We further discuss how infection-responsive dynamic logic circuits and the systematic identification of Vero-specific genomic safe harbors could shift the paradigm from static trait installation toward a continuously programmable, conditionally responsive manufacturing architecture. Collectively, these advances suggest a pathway for transitioning the Vero lineage from a passive biological substrate into a programmable platform capable of meeting the accelerated timelines and distributed manufacturing imperatives of modern global health preparedness.